Note: The below is an edited version of an article originally published on Yahoo Finance. The original release can be read in it’s entirety here.
CSL Behring announced new data today from its Phase III PROLONG-9FP clinical development program evaluatingÂ IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s long-acting recombinant albumin fusion protein for treating hemophilia B. The data, from a Phase III study and an ongoing extension study, assessed the long-term efficacy and safety ofÂ IDELVIONÂ for routine prophylaxis in previously treated children and adults with hemophilia B. The results showed that extended prophylaxis treatment regimens effectively prevented bleeds while also reducing overallÂ IDELVIONÂ consumption.